Predictors of sustained response to infliximab in patients with Crohn´s disease: a single cohort study
Abstract
Sustained response to IFX was observed in about two thirds of CD patients. Therapeutic IFX levels at start of maintenance regime and concomitant immunosuppressive therapy were associated with sustained clinical benefit, whereas need for corticosteroids at IFX initiation increased the risk of IFX failure.